Format

Send to

Choose Destination
Semin Oncol. 2014 Aug;41(4):511-522. doi: 10.1053/j.seminoncol.2014.06.010. Epub 2014 Jun 30.

Medical management of high-grade astrocytoma: current and emerging therapies.

Author information

1
Department of Neurology, Mayo Clinic, Rochester, MN. Electronic address: johnson.derek1@mayo.edu.
2
Department of Oncology, Division of Medical Oncology, Department of Molecular Medicine, Mayo Clinic, Rochester, MN.

Abstract

High-grade astrocytomas are aggressive and incurable primary brain tumors. Radiation therapy with concurrent and adjuvant temozolomide chemotherapy is the standard-of-care treatment for newly diagnosed glioblastoma, while the role of chemotherapy in the initial treatment of anaplastic astrocytoma is evolving. Currently available medical options at tumor progression include further cytotoxic therapy and the vascular endothelial growth factor (VEGF) inhibitor bevacizumab. Investigational treatments including numerous molecularly targeted agents and immunotherapeutic approaches are currently being evaluated. Significant future progress will require better understanding and exploitation of the molecular heterogeneity within high-grade astrocytoma, as well as innovative trial designs to evaluate efficiently targeted therapies in the subsets of patients in which they are most likely to be effective.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center